Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback